Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer

Crouch, Brian T.; Gallagher, Jennifer E.; Wang, Roujia; Duer, Joy; Hall, Allison; Soo, Mary Scott; Hughes, Philip F.; Haystead, Timothy; Ramanujam, Nirmala

doi:10.1038/s41598-019-40252-y

Cited by 12 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In [ 15 ], the authors devised a strategy using HS-27, for determining Hsp90 expression from tissue specimens for the diagnosis of breast cancer. Findings revealed that the HS-27 value was the highest in tumour tissues.…”

Section: Introductionmentioning

confidence: 99%

Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

Zhou

Yang

Wang

et al. 2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Lung cancer is a lethal disease, and early diagnosis with the aid of biomarkers such as HSP90α protein can certainly assist the doctors to start treatment of patient at the earliest and can save their lives. To analyse the diagnostic value of HSP90α expression in lung cancer patients by collecting data of patients through IoT devices to avoid delay in treatments, a study has been presented in this paper where the significance of HSP90α biomarker is highlighted in early diagnosis of patients suffering from lung cancer. The second objective of the research study is to examine the correlation between the appearance level of HSP90α biomarker and the clinicopathological features of lung cancer. It is also evaluated whether the changes in HSP90α index are indicative or noteworthy before and after surgery of lung cancer patients. An observatory study of 78 patients with lung cancer in Qinhuangdao Hospital is presented in this paper where the samples were collected from June 2018 to March 2020. Their data were collected through IoT devices used in the latest healthcare facilities of the hospital. The ELISA method was utilized to identify the level of plasma HSP90 and to analyse HSP90 levels between the lung cancer group and healthy group of people. The relationship between HSP90 and the clinical pathological features of 78 patients suffering from lung cancer was analysed. An electrochemical luminescence method was used to detect CEA, NSE, SCC, and CYFRA21-1 levels. ROC curve and box plots were used to determine the analytic value of HSP90 and other biomarkers used in lung cancer diagnosis. Forty-two patients with moderate to early stage lung cancer with surgical correction were selected, and paired sample T test was used to analyse HSP90 levels before and after surgery. The plasma HSP90 level of lung cancer patients was quite higher as compared to the group of healthy people as per the values depicted in the research study. Second, HSP90 levels are substantially higher in pathologic type, differentiation degree, stage, and the existence of the lung, liver, and bone metastases ( P < 0.05). The level of HSP90 expression was largely impacted by a few factors such as sex, age, smoking, and tumour location ( P > 0.05). The ROC value for HSP90 was 0.599, while the area under the curve of HSP90 combined with other four tumour markers was 0.915 in the presented case study, indicating the presence of lung cancer. Patients with lung cancer had statistically significant differences in HSP90 expression levels before and after surgery ( P < 0.05). It is concluded that the expression level of plasma HSP90α in lung cancer patients increases remarkably; therefore, HSP90 can be used to monitor presence of lung cancer before and after surgery in the patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

Zhou

Yang

Wang

et al. 2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…The protein levels of HSP90AA1 were significantly elevated in tumors compared to normal mammary glands ( Vartholomaiou et al, 2017 ). This was also observed in a breast cancer diagnostic study; they used fluorescein HS-27 in combination with HSP90 to provide a cost-effective and easy-to-implement diagnostic platform ( Crouch et al, 2019 ). The biochemical assessment may lead to savings of almost 50% compared with medical imaging techniques ( Robertson et al, 1995 ).…”

Section: Discussionmentioning

confidence: 72%

Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis

Liu

Zhang

Huang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

AimWe aimed to develop and validate a comprehensive nomogram containing pre-treatment plasma HSP90AA1 to predict the risk of breast cancer onset and metastasis.MethodsWe assessed the expression of HSP90s in breast cancer patients using an online database. To verify the results, 677 patients diagnosed with breast cancer and 146 patients with benign breast disease between 2014 and 2019 were selected from our hospital and were divided into cancer risk and metastasis risk cohorts. We focused on HSP90AA1 to elucidate the risks of onset and metastasis in the cohorts.ResultsExpression levels of HSP90AA1, HSP90AA2, HSP90AB1, HSP90B1, and TRAP1 were linked to disease progression. Survival analysis using the GEPIA and OncoLnc databases indicated that the upregulation of HSP90AA1 and HSP90AB1 was related to poor overall survival. In the cancer risk cohort, carcinoembryonic antigen (CEA), carbohydrate antigen 153 (CA153), HSP90AA1, T cells%, natural killer cells%, B cells%, neutrophil count, monocyte count, and d-dimer were incorporated into the nomogram. A high Harrell’s concordance index (C-index) value of 0.771 [95% confidence interval (CI), 0.725–0.817] could still be reached in the interval validation. In the metastasis risk cohort, predictors contained in the prediction nomogram included the use of CEA, CA153, HSP90AA1, carbohydrate antigen 125 (CA125), natural killer cells%, B cells%, platelet count, monocyte count, and d-dimer. The C-index was 0.844 (95% CI, 0.801–0.887) and it was well-calibrated. HSP90AA1 raised net clinical benefit of breast cancer onset and metastasis risk prediction nomogram in a range of risk thresholds (5–92%) and (1–90%).ConclusionOur study revealed that pretreatment plasma HSP90AA1 combined with other markers could conveniently predict the risk of breast cancer onset and metastasis.

show abstract

“…In addition to intrinsic fluorescence contrast, several promising fluorescent molecular probes have been explored to improve tumor identification in tumor margins. For example, our lab has explored the imaging of fluorescence labeled heat shock protein 90 (Hsp90) on core needle biopsies for rapid breast cancer diagnosis [38,39]. By modifying our device to perform fluorescence imaging, our device can generate co-registered brightfield and fluorescence images [40].…”

Section: Discussionmentioning

confidence: 99%

A color‐based tumor segmentation method for clinical ex vivo breast tissue assessment utilizing a multi‐contrast brightfield imaging strategy

Wang,

Ekem,

Gallagher

et al. 2024

Journal of Biophotonics

Self Cite

View full text Add to dashboard Cite

We demonstrate an automated two‐step tumor segmentation method leveraging color information from brightfield images of fresh core needle biopsies of breast tissue. Three different color spaces (HSV, CIELAB, YCbCr) were explored for the segmentation task. By leveraging white‐light and green‐light images, we identified two different types of color transformations that could separate adipose from benign and tumor or cancerous tissue. We leveraged these two distinct color transformation methods in a two‐step process where adipose tissue segmentation was followed by benign tissue segmentation thereby isolating the malignant region of the biopsy. Our tumor segmentation algorithm and imaging probe could highlight suspicious regions on unprocessed biopsy tissue to guide selection of areas most similar to malignant tissues for tissue pathology whether it be formalin fixed or frozen sections, expedite tissue selection for molecular testing, detect positive tumor margins, or serve an alternative to tissue pathology, in countries where these services are lacking.

show abstract

Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer

Cited by 12 publications

References 50 publications

Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis

A color‐based tumor segmentation method for clinical ex vivo breast tissue assessment utilizing a multi‐contrast brightfield imaging strategy

Contact Info

Product

Resources

About